

Pathogen Safety of Long-Term Treatments for Bleeding Disorders: (Un)Predictable Risks and Evolving Threats

Giovanni Di Minno, MD, PharmD¹ Mariana Canaro, MD² James W. Ironside, BMSc, MBChB³
David Navarro, MD PhD⁴ Carlo F. Perno, MD, PhD⁵ Andreas Tiede, MD, PhD⁶ Lutz Guertler, MD, PhD⁷

¹ Department of Clinical Medicine and Surgery, Regional Reference Centre for Coagulation Disorders, Napoli, Italy

² Department of Hemostasis and Thrombosis, Son Espases University Hospital, Palma de Mallorca, Spain

³ National Creutzfeldt-Jakob Disease Surveillance Unit, School of Molecular and Clinical Medicine, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom

⁴ Department of Microbiology, Microbiology Service, Hospital Clínico Universitario, School of Medicine, University of Valencia, Valencia, Spain

⁵ Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy

⁶ Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

⁷ Max von Pettenkofer Institute for Hygiene and Medical Microbiology, University of München, Munich, Germany

Address for correspondence Giovanni Di Minno, MD, PharmD, Dipartimento di Medicina Clinica e Chirurgia, Regional Reference Centre for Coagulation Disorders, Federico II University, Via S. Pansini 5, 80131 Naples, Italy (e-mail: diminno@unina.it).

Semin Thromb Hemost 2013;39:973.

ERRATUM

The authors regret mentioning potential misinformation for few products in Tables 2 and 3 of the above article (Volume 39, Number 7, pp. 782–786). The complete details and updates are summarized below:

Page No.	Column head	Row	Potential misinformation	Corrected information
Table 2				
783	Potential risks	Kogenate FS (Bayer)	Allergic type hypersensitivity reactions; risk of infection from unknown/emerging viral/other pathogens; risk of thrombotic events; formation of neutralizing antibodies; thrombophlebitis/thrombosis at infusion/catheter site	Allergic type hypersensitivity reactions; risk of thrombotic events; formation of neutralizing antibodies; thrombophlebitis/thrombosis at infusion/catheter site
784	Potential risks	Xyntha/ ReFacto AF (Pfizer)	Allergic type hypersensitivity reactions; risk of infection from unknown/emerging viral/other pathogens; formation of neutralizing antibodies; lack of effect (bleeding events)	Allergic type hypersensitivity reactions; formation of neutralizing antibodies; lack of effect (bleeding events)
Table 3				
786	Purification	BeneFIX (Pfizer)	Immunoaffinity chromatography	Affinity chromatography

Issue Theme Issue Theme Old and New Challenges in Hemophilia Management; Guest Editors, Antonio Coppola, MD, Annarita Tagliaferri, MD, and Massimo Franchini, MD.

Copyright © 2013 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
Tel: +1(212) 584-4662.

DOI <http://dx.doi.org/10.1055/s-0033-1358798>.
ISSN 0094-6176.